HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm

被引：0
|
作者：
T Van Gorp
I Cadron
E Despierre
A Daemen
K Leunen
F Amant
D Timmerman
B De Moor
I Vergote
机构：
[1] Universitaire Ziekenhuizen Leuven,Division of Gynaecological Oncology, Department of Obstetrics and Gynaecology
[2] Katholieke Universiteit Leuven,Division of Gynaecological Oncology, Department of Obstetrics and Gynaecology
[3] Herestraat 49,Department of Electrical Engineering
[4] MUMC+,undefined
[5] GROW – School for Oncology and Developmental Biology,undefined
[6] ESAT-SCD/SISTA,undefined
[7] Katholieke Universiteit Leuven,undefined
[8] Kasteelpark Arenberg 10,undefined
来源：
British Journal of Cancer | 2011年 / 104卷
关键词：
HE4; CA125; ovarian cancer; Risk of Ovarian Malignancy Algorithm;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：863 / 870
页数：7
相关论文
共 50 条
  • [21] A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index
    Lycke, Maria
    Kristjansdottir, Bjorg
    Sundfeldt, Karin
    GYNECOLOGIC ONCOLOGY, 2018, 151 (01) : 159 - 165
  • [22] Modification of Cutoff Values for HE4, CA125, the Risk of Malignancy Index, and the Risk of Malignancy Algorithm for Ovarian Cancer Detection in Jakarta, Indonesia
    Winarto, Hariyono
    Laihad, Bismarck Joel
    Nuranna, Laila
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (05) : 1949 - 1953
  • [23] CA125 and HE4: Measurement Tools for Ovarian Cancer
    Zhao, Tingting
    Hu, Weiping
    GYNECOLOGIC AND OBSTETRIC INVESTIGATION, 2016, 81 (05) : 430 - 435
  • [24] Evaluation of CA125 and HE4 diagnostic performance in hereditary and sporadic ovarian cancer
    Tartaglione, S.
    Manganaro, L.
    Di Trani, M.
    Viggiani, V.
    Tomao, F.
    Angeloni, A.
    Anastasi, E.
    CLINICA CHIMICA ACTA, 2019, 493 : S158 - S159
  • [25] Symptoms, CA125 and HE4 for the preoperative prediction of ovarian malignancy in Brazilian women with ovarian masses
    Denise da Rocha Pitta
    Luis Otávio Sarian
    Amilcar Barreta
    Elisabete Aparecida Campos
    Liliana Lucci de Angelo Andrade
    Ana Maria Dias Fachini
    Leonardo Martins Campbell
    Sophie Derchain
    BMC Cancer, 13
  • [26] Evaluation of serum CA125, HE4 and CA724 and the risk of ovarian malignancy algorithm score in the diagnosis of high-grade serous ovarian cancer
    Hu, Deyu
    Qian, Jun
    Yin, Fenghua
    Wei, Bing
    Wang, Jiayu
    Zhang, Huijuan
    Yang, Haiou
    EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2024, 297 : 170 - 175
  • [27] Symptoms, CA125 and HE4 for the preoperative prediction of ovarian malignancy in Brazilian women with ovarian masses
    Pitta, Denise da Rocha
    Sarian, Luis Otavio
    Barreta, Amilcar
    Campos, Elisabete Aparecida
    de Angelo Andrade, Liliana Lucci
    Dias Fachini, Ana Maria
    Campbell, Leonardo Martins
    Derchain, Sophie
    BMC CANCER, 2013, 13
  • [28] Influence of Ovarian Cancer Risk Status on the Diagnostic Performance of the Serum Biomarkers Mesothelin, HE4, and CA125
    Shah, Chirag A.
    Lowe, Kimberly A.
    Paley, Pamela
    Wallace, Erin
    Anderson, Garnet L.
    McIntosh, Martin W.
    Andersen, M. Robyn
    Scholler, Nathalie
    Bergan, Lindsay A.
    Thorpe, Jason D.
    Urban, Nicole
    Drescher, Charles W.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2009, 18 (05) : 1365 - 1372
  • [29] A combined strategy of TK1, HE4 and CA125 shows better diagnostic performance than risk of ovarian malignancy algorithm (ROMA) in ovarian carcinoma
    Zhu, Cheng
    Zhang, Nenghua
    Zhong, Ailing
    Xiao, Kangjia
    Lu, Renquan
    Guo, Lin
    CLINICA CHIMICA ACTA, 2022, 524 : 43 - 50
  • [30] The diagnostic performance of the Mindray system in detecting CA125 and HE4 for patients with ovarian cancer
    Feng, Pingfeng
    Chen, Tao
    Wischhusen, Joerg
    Ladbury, Colton
    Vargas-Hernandez, Victor Manuel
    Xiong, Yufeng
    TRANSLATIONAL CANCER RESEARCH, 2024, 13 (08)
12345